Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02918513
Other study ID # 2016-07-0021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date August 13, 2018

Study information

Verified date April 2019
Source University of Texas at Austin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.


Description:

This study involves participating in a 90-day integrated, prescriptive, trackable wellness intervention, which includes five wellness elements: exercise, mindfulness, sleep, social connectedness, and nutrition.

The intervention is divided into three phases (each spanning 30-days): Phase 1 - 'Boot Camp', Phase 2 - Solidify, and Phase 3 - Sustain. Program requirements include: Implementing 5 wellness interventions daily for the first 30-days, at least 5 days for the next 30-days, and at least 3 days for the final 30-days, documenting daily online adherence, completing daily wellness exercises to improve mental wellness, and completing online program forms prior to beginning the program, at 30-days, and again at 90-days.

Once eligibility is confirmed via the initial orientation/screening call, study personnel will mail each participant a WILD 5 Wellness Workbook within one day of emailing participants their unique identification codes plus their start dates. Participants will be instructed to document adherence regarding their daily wellness practices and their daily wellness exercises online via Qualtrics, an online survey software. Participants can document their daily adherence using their computer and/or their smartphone as Qualtrics offers a mobile version of the Participant Tracking Form. A copy of the Participant Tracking Form will also be available in the WILD 5 Workbook so participants that prefer keeping a daily paper log can do so, and they can then transfer their program adherence information to the online Participant Tracking Form throughout the program. The workbook will contain the participant's personal identification code; no personal identification will appear in the workbook in order to protect participant confidentiality.

One day prior to a participant's start date, which will be set during the orientation/screening call, participants will receive an automated email from an online automated email service (MailChimp), with a reminder about their start date, and encouragement to contact study personnel with any questions or concerns.

Participants will also receive daily motivational emails from an online automated email service (MailChimp), which will provide general information about one of the five wellness elements and/or one of the wellness exercises, as well as encouragement to track their participation on a daily basis, and encouragement to contact study personnel via email with any questions and/or concerns.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date August 13, 2018
Est. primary completion date June 12, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (18 years of age or older)

- English- speaking

- Access to a reliable Internet-enabled computer

- Possess basic computer skills

- Self-identify as having at least one of the health conditions listed on the online registration form or

- Self-identify as a community participant without a health condition.

Exclusion Criteria:

- Acutely suicidal and/or actively psychotic

- Non-English speaking

- Do not have access to an Internet-enabled computer

- Report a lack of basic computer skills

- Pregnant or plan to get pregnant during the next 90-days.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Wellness Element 1 - Exercise
1. Daily wellness element focusing on Exercise; adherence documented online daily
Wellness Element 2 - Mindfulness
2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
Wellness Element 3 - Sleep Hygiene
3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
Wellness Element 4 - Social Connectedness
4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
Wellness Element 5 - Nutrition
5. Daily wellness element focusing on Nutrition; adherence documented online daily
Wellness Element 6 - Wellness Exercises
6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
Wellness Element 7 - Motivational Messages
7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)

Locations

Country Name City State
United States University of Texas at Austin School of Nursing Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

References & Publications (6)

Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE. Exercise for depression. Cochrane Database Syst Rev. 2013 Sep 12;(9):CD004366. doi: 10.1002/14651858.CD004366.pub6. Review. — View Citation

Cruwys T, Dingle GA, Haslam C, Haslam SA, Jetten J, Morton TA. Social group memberships protect against future depression, alleviate depression symptoms and prevent depression relapse. Soc Sci Med. 2013 Dec;98:179-86. doi: 10.1016/j.socscimed.2013.09.013. — View Citation

Fardet A, Boirie Y. Associations between food and beverage groups and major diet-related chronic diseases: an exhaustive review of pooled/meta-analyses and systematic reviews. Nutr Rev. 2014 Dec;72(12):741-62. doi: 10.1111/nure.12153. Epub 2014 Nov 18. Re — View Citation

Hui SK, Grandner MA. Associations between Poor Sleep Quality and Stages of Change of Multiple Health Behaviors among Participants of Employee Wellness Program. Prev Med Rep. 2015 Jan 1;2:292-299. — View Citation

Jeste DV, Palmer BW, Rettew DC, Boardman S. Positive psychiatry: its time has come. J Clin Psychiatry. 2015 Jun;76(6):675-83. doi: 10.4088/JCP.14nr09599. — View Citation

Williams JM, Crane C, Barnhofer T, Brennan K, Duggan DS, Fennell MJ, Hackmann A, Krusche A, Muse K, Von Rohr IR, Shah D, Crane RS, Eames C, Jones M, Radford S, Silverton S, Sun Y, Weatherley-Jones E, Whitaker CJ, Russell D, Russell IT. Mindfulness-based c — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Patient Health Questionnaire-9 (PHQ-9) A self-reported depression scale used to assess severity of depression. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in Generalized Anxiety Disorder-7 (GAD-7) A self-reported questionnaire used to assess anxiety symptoms. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in World Health Organization-5 (WHO-5) A brief scale that measures mental well- being. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Mindful Attention Awareness Scale (MAAS) A popular measure of mindfulness. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Sleep Condition Indicator (SCI) A brief scale that evaluates insomnia disorder. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Social Connectedness Scale (SCS) A brief scale that assesses the degree to which respondents feel connected to others. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in Eating and Appraisal Due to Emotions and Stress (EADES) A scale assessing how individuals cope with and appraise stress in relation to food and eating. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) A combination of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets shown to lower a person's risk of developing Alzheimer's disease. 0, 30, and 90 - Primary endpoint is 30 days
Primary Change in The Brief Pain Inventory (BPI) A measurement tool for assessing clinical pain. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Sheehan Disability Scale (SDS) A measurement tool for assessing functional impairment in three inter-related domains: work/school, social and family life. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The Endicott Work Productivity Scale (EWPS) A brief self-report questionnaire designed to obtain a sensitive measure of work productivity. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in Cognitive and Physical Functioning Questionnaire (CPFQ) A brief scale that measures cognitive and executive dysfunction. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The WILD 5 Wellness Scale (W5WS) A brief scale designed specifically for this project to measure wellness. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The WILD 5 Wellness Effort Scale (W5ES) A scale designed specifically for this project to measure weekly adherence with program elements. 0, 30, and 90 days - Primary endpoint is 30 days
Primary Change in The WILD 5 Wellness Elements Scale A scale designed specifically for this project to measure elements of depression, anxiety, wellbeing, mindfulness, sleep quality, social connectedness, emotional eating, diet practices, pain, disability, work productivity, happiness, enthusiasm, resilience, and optimism. 0, 30, and 90 days - Primary endpoint is 30 days
Primary The Post-Program Participant Questionnaire A brief post study survey that captures participants' opinions about WILD 5 Wellness: 90-Day Intervention, and subjective ranking of their overall wellness. 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1